Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

FDA delays Capricor's deramiocel PDUFA date to review new data

24 August 2026 · By · Wire by Fusion42

Published

24 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at endpoints.news →

◆ Verified

Fusion42 · 25 August 2026 · Fusion42 review

The FDA has delayed its decision on Capricor Therapeutics' Duchenne muscular dystrophy therapy deramiocel to review new data submitted for a more niche indication.

This Wire brief sits within Fusion42's coverage of Biotech, and 5 sources have reported it between 14 Aug 2026 and 24 Aug 2026.

◆ ◆ The Wire takeaway

You face a longer wait for FDA approval of Capricor's Duchenne therapy, increasing the urgency to explore alternative revenue pathways or accelerate other pipeline assets.

◆ Coverage

5 sources · first reported 14 Aug 2026 · latest 24 Aug 2026

◆ Related on Wire

◆ Topics

Biotechfdabiotechdrug-approvalmuscular-dystrophyclinical-data